Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial

By afschroeder • March 3, 2026

Durstenfeld MS, Levkova-Clark M, Ms DL, Schaffer V, Abohashem S, Ma Y, Kawai K, Lu MT, Sereti I, Deeks SG, Tawakol A, Hsue PY. Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial. Am Heart J. 2026 Feb 28:107400. doi: 10.1016/j.ahj.2026.107400. Epub ahead of print. PMID: 41771366.

Tags: arterial inflammation, Cardiology/Epi, Cholesterol, Clinical Trial, Coronary Atherosclerosis, HIV, PCSK9, Publications

Maternal hyperglycemia disrupts cardiomyocyte maturation via aberrant nucleotide metabolism and suppression of AMPK signaling

Nakano H, Kawahira N, Vesprey A, Nakano A. Maternal hyperglycemia disrupts cardiomyocyte maturation via aberrant nucleotide metabolism and suppression of AMPK signaling. Cell Rep. 2026[...]

Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN)

Hamilton DE, Shriver JL, Patel SM, Park JG, Michos ZE, Mathis MR, Adie SK, Alviar CL, Barnett CF, Berg DD, Bennett CE, Bohula EA, Carnicelli[...]

National Evaluation of Racial, Ethnic, and Insurance-Based Disparities in Interhospital Transfer of Patients With Ischemic Stroke

Turner AC, Li S, Wahab F, Zhao J, Thomas K, Poudel R, Reeves M, Smith EE, Messé SR, Fonarow GC, Schwamm LH, Zachrison KS. National[...]